Chief Scientific Officer

Build the scientific direction of a next-generation AI-enabled biotech.

Antiverse is looking for a Chief Scientific Officer to help shape the next chapter of the company. This is a rare opportunity to join an AI-driven antibody discovery business at a pivotal stage of growth and determine not only which programmes move forward, but what the company becomes over the next decade.

We're looking for a scientific leader who can combine deep disease biology expertise with exceptional strategic judgement, helping to connect biology, technology, AI and therapeutics into a differentiated platform and pipeline.

Antiverse is an AI-driven biotech company developing antibodies against some of the most difficult targets in medicine, including GPCRs and ion channels.

By combining machine learning, advanced cell engineering, antibody discovery and high-throughput biology, the company is building a platform designed to create therapeutics that were previously difficult or impossible to discover.

The next phase of growth is not simply about discovering more antibodies.

It's about building a world-class, disease-informed platform capable of repeatedly generating better therapeutic opportunities.

• Idiopathic Pulmonary Fibrosis (IPF)
• MASH / metabolic disease
• Inflammatory diseases
• Complex biologics and antibody therapeutics

You will work directly with the CEO, leadership team, board, investors and scientific teams to determine:

• Which disease areas Antiverse should prioritise
• Which targets deserve investment
• Which datasets should be generated
• Which biological systems should be built
• How experimental biology and AI should work together
• How the platform evolves over time
• How programmes are progressed from hypothesis to partner-ready assets

This role is as much about scientific judgement as it is scientific expertise.

• Defining Antiverse's scientific strategy and long-term direction
• Building and evolving therapeutic area strategy
• Advancing programmes within IPF and MASH
• Leading target identification and prioritisation activities
• Developing disease-informed platform strategy
• Guiding translational biology and pharmacology efforts
• Defining in vitro and in vivo validation strategies
• Working closely with AI and machine learning teams to shape dataset generation
• Leading progression of antibody programmes from discovery through preclinical development
• Supporting partnering, licensing and external collaborations
• Acting as a key scientific representative for investors, pharmaceutical partners and advisors
• Building and mentoring a high-performing scientific organisation

• Significant scientific leadership experience within biotech or pharmaceutical drug discovery
• Deep expertise in IPF, MASH, fibrosis, metabolic disease, inflammation or closely related biology
• Strong biologics and/or antibody discovery background
• Experience progressing programmes through discovery and preclinical development